← All indications
Liver Failure
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Subtype terms (3)
More specific conditions that are subtypes of Liver Failure in the MeSH hierarchy.
- End Stage Liver Disease
41 drugs (29 approved, 12 experimental)
- Hepatic Encephalopathy
76 drugs (42 approved, 34 experimental)
- Liver Failure, Acute
28 drugs (17 approved, 11 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (14)
Phase 3 trials (11)
Phase 2 trials (20)
- maltodextrin
- adefovir dipivoxil
- acetylcysteine
- prednisone
- fomepizole
- hepatocyte
- emricasan
- lamivudine
- allogeneic hematopoietic stem cells
- ribavirin
- everolimus
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- umbilical cord mesenchymal stem cells
- autologous mesenchymal stem cells
- raltegravir
- ademetionine1,4-butanethiosulfonate
- 1,4-butanethiosulfonate
- branched chain amino acids
- qel-001
Phase 1 trials (12)
Organizations
Organization Involved with Phase 4 Indications (17)
- Indivior Inc.
- Boehringer Ingelheim
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Manitoba
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- Medical University of Warsaw
- Menoufia University
- Postgraduate Institute of Medical Education and Research
- Stanley Dudrick's Memorial Hospital
- University of Basel
- Orlando Clinical Research Center
- Clinical Pharmacology of Miami
- American Research Corporation (ARC)
- Erasmus University Rotterdam
- Government of Egypt
- People's Liberation Army of China
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (25)
- Merck
- Grifols
- Mylan
- CardiOx Corporation
- Exalenz Bioscience LTD.
- Humedics GmbH
- Madaus Inc
- University of Pittsburgh
- Katholieke Universiteit Leuven
- Korea University
- Pavol Jozef Safarik University
- University of Groningen
- University of Michigan
- Fudan University
- Institute of Liver and Biliary Sciences, India
- Medical University of South Carolina
- Leiden University
- Asian Institute of Gastroenterology
- Dominican Santa Cruz Hospital
- University of Paris
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
- Pharmbio Korea
- Assistance Publique - Hôpitaux de Paris
- Nhat Nhat Pharmaceutical Company
- Dr. F. Köhler Chemie GmbH
Organization Involved with Phase 2 Indications (38)
- Gilead Sciences
- Alfact Innovation
- Betta Pharmaceuticals Co.,Ltd.
- FGK Clinical Research GmbH
- Ocera Therapeutics
- Rheacell GmbH & Co. KG
- Veloxis Pharmaceuticals
- Promethera Biosciences
- French National Agency for Research on AIDS and Viral Hepatitis
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pennsylvania
- University of London
- Kyoto University
- University of Heidelberg
- University of Nottingham
- University of Padova
- University of Rochester
- University of South Carolina
- University of South Florida
- University of Bern
- Virginia Commonwealth University
- Tianjin University of Traditional Chinese Medicine
- University of Cincinnati
- University of Copenhagen
- All India Institute of Medical Sciences
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- Conatus Pharmaceuticals
- Louisiana State University
- Chu De Liège
- Sun Yat-Sen University
- +8 more
Organization Involved with Phase 1 Indications (48)
- Abbott
- Acorda Therapeutics
- Javelin Pharmaceuticals
- ViroPharma
- Bristol-Myers Squibb
- Vertex
- Debiopharm
- Roche
- Astellas
- Immunomedics
- AstraZeneca
- Medivation
- Eli Lilly
- Genentech
- Pfizer
- Wyeth
- Novartis
- Ariad Pharmaceuticals
- Bayer
- BeOne Medicines
- Biotie Therapies
- FibroGen
- Mochida Pharmaceutical Company, Ltd.
- Neurocrine Biosciences
- Tobira Therapeutics, Inc.
- Fuji Yakuhin Co., Ltd.
- PharmaMar
- Puma Biotechnology, Inc.
- Steminent Biotherapeutics Inc.
- National Cancer Institute (NCI)
- +18 more
Organization Involved with Other Experimental Indications (24)
- Huazhong University of Science and Technology
- Aarhus University
- Eastern Hepatobiliary Surgery Hospital
- Emory University
- Guangxi Medical University
- Jilin University
- Shanghai University of Traditional Chinese Medicine
- Shenzhen Third People's Hospital
- University of Leipzig
- Capital Medical University
- Columbia University
- Hunan University of Traditional Chinese Medicine
- Xiamen University
- Southern Medical University
- Government of China
- Henan Medical University
- Hepatobiliary Disease Hospital of Jilin Province, Jilin, China
- University of Gothenburg
- Shenzhen University
- China Medical University
- Hubei University of Chinese Medicine
- Fuzhou Infectious Hospital
- Hangzhou Xixi hospital
- Axcella Health Inc.